Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platelet-derived mitochondria (pl-MT) are isolated mitochondria obtained from platelets, used as a therapeutic agent in mitochondrial transplantation. In the context of endometriosis, pl-MT transplantation aims to modulate the inflammatory microenvironment by shifting macrophage polarization from a pro-inflammatory M1 phenotype toward a less inflammatory state. This process involves the restoration of mitochondrial function, promoting oxidative phosphorylation over aerobic glycolysis (the Warburg effect), and suppressing fibrosis and inflammation in ectopic endometrial tissue. Research indicates that these transplanted mitochondria can maintain structural integrity and membrane potential, biodistribute to target tissues, and significantly reduce lesion volume.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on platelet-derived mitochondria.